<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092677</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-043</org_study_id>
    <secondary_id>2004_050</secondary_id>
    <nct_id>NCT00092677</nct_id>
  </id_info>
  <brief_title>An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Ezetimibe + Simvastatin on Clinical Outcomes in Patients With Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether treatment with an investigational drug as
      compared to placebo will reduce the risk of major cardiovascular events in patients with
      aortic stenosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Composite endpoint of MCE consists of cardiovascular death, AVR (aortic valve replacement) surgery, CHF(congestive heart failure) as a result of progression of aortic stenosis, nonfatal MI (myocardial infarction), CABG (coronary artery bypass) surgery, PCI (percutaneous coronary intervention), hospitalized unstable angina, and nonhemorrhagic stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Composite endpoint of AVE (aortic valve events) consists of AVR surgery, CHF (as a result of progression of AS), or cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Composite endpoint of ICE (ischemic cardiovascular events) consists of cardiovascular death, nonfatal MI, CABG, PCI, hospitalized unstable angina, and nonhemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Transaortic Jet Velocity</measure>
    <time_frame>Baseline to End of follow-up (median = 4.35 years) or pre-aortic valve replacement</time_frame>
    <description>Mean change from baseline in peak transaortic jet velocity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that experienced cardiovascular death</description>
  </other_outcome>
  <other_outcome>
    <measure>Aortic Valve Replacement (AVR)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that experienced aortic valve replacement (AVR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that experienced Congestive Heart Failure (CHF) due to progression of aortic stenosis (AS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Nonfatal Myocardial Infarction (MI)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that experienced nonfatal myocardial infarction (MI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Coronary Artery Bypass Grafting (CABG)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that experienced coronary artery bypass grafting (CABG)</description>
  </other_outcome>
  <other_outcome>
    <measure>Percutaneous Coronary Intervention (PCI)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that experienced percutaneous coronary intervention (PCI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalization for Unstable Angina</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that experienced hospitalization for unstable angina</description>
  </other_outcome>
  <other_outcome>
    <measure>Nonhemorrhagic Stroke</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that experienced nonhemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Death (Any Cause)</measure>
    <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
    <description>Number of participants that died (any cause)</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Time Weighted Average Total Cholesterol From Baseline to End of Follow-up</measure>
    <time_frame>Baseline to End of follow-up (median = 4.35 years)</time_frame>
    <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Time Weighted Average Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to End of Follow-up</measure>
    <time_frame>Baseline to End of follow-up (median = 4.35 years)</time_frame>
    <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Time Weighted Average High-density Lipoprotein Cholesterol (HDL-C) From Baseline to End of Follow-up</measure>
    <time_frame>Baseline to End of follow-up (median = 4.35 years)</time_frame>
    <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Time Weighted Average Triglycerides From Baseline to End of Follow-up</measure>
    <time_frame>Baseline to End of follow-up (median = 4.35 years)</time_frame>
    <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1873</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>EZ/Simva 10/40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>Duration of Treatment: 4 years</description>
    <arm_group_label>EZ/Simva 10/40 mg</arm_group_label>
    <other_name>MK0653A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 45 to 85 with mild abnormalities of the aortic valve as confirmed by an
             echocardiogram.

        Exclusion Criteria:

          -  Patients previously in a trial using the study drug, or currently taking any
             medications that are not allowed in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008 Sep 25;359(13):1343-56. doi: 10.1056/NEJMoa0804602. Epub 2008 Sep 2.</citation>
    <PMID>18765433</PMID>
  </reference>
  <reference>
    <citation>Steine K, Rossebø AB, Stugaard M, Pedersen TR. Left ventricular systolic and diastolic function in asymptomatic patients with moderate aortic stenosis. Am J Cardiol. 2008 Oct 1;102(7):897-901. doi: 10.1016/j.amjcard.2008.07.001. Epub 2008 Aug 26.</citation>
    <PMID>18805118</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2004</study_first_submitted>
  <study_first_submitted_qc>September 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2004</study_first_posted>
  <results_first_submitted>March 31, 2009</results_first_submitted>
  <results_first_submitted_qc>March 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2009</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III. Study Initiation Date (FPI) was 06-Jan-2003 and Study Completion Date (LPO) was 17-Apr-2008. Primary therapy period 02-Mar-2001 to 31-Mar-2008 includes start date of therapy from the Simvastatin in Aortic Stenosis (SAS) study. 173 study centers worldwide (Denmark, Finland, Germany, Great Britain, Ireland, Norway, and Sweden)</recruitment_details>
      <pre_assignment_details>Included patients with asymptomatic aortic stenosis as assessed on echocardiography, not requiring lipid-lowering therapy, and without known coronary heart disease or diabetes mellitus. 4 week placebo/diet run-in period was followed by treatment period lasting until 4 years after the last patient was randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EZ/Simva 10/40 mg</title>
          <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="944"/>
                <participants group_id="P2" count="929"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="939">EZ/Simva: 694 (on drug), 140 (after drug discon), 105 (at death)</participants>
                <participants group_id="P2" count="918">Placebo: 698 (on drug), 120 (after drug discon), 100 (at death)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adminstrative</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EZ/Simva 10/40 mg</title>
          <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="944"/>
            <count group_id="B2" value="929"/>
            <count group_id="B3" value="1873"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" lower_limit="41" upper_limit="86"/>
                    <measurement group_id="B2" value="67.4" lower_limit="28" upper_limit="85"/>
                    <measurement group_id="B3" value="67.5" lower_limit="28" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                    <measurement group_id="B2" value="360"/>
                    <measurement group_id="B3" value="723"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="581"/>
                    <measurement group_id="B2" value="569"/>
                    <measurement group_id="B3" value="1150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="940"/>
                    <measurement group_id="B2" value="928"/>
                    <measurement group_id="B3" value="1868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density Lipoprotein Cholesterol (HDL-C)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.49" spread="0.43"/>
                    <measurement group_id="B2" value="1.49" spread="0.43"/>
                    <measurement group_id="B3" value="1.49" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.62" spread="0.93"/>
                    <measurement group_id="B2" value="3.59" spread="0.91"/>
                    <measurement group_id="B3" value="3.60" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak Transaortic Jet Velocity</title>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.09" spread="0.55"/>
                    <measurement group_id="B2" value="3.10" spread="0.54"/>
                    <measurement group_id="B3" value="3.09" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.76" spread="1.04"/>
                    <measurement group_id="B2" value="5.73" spread="0.99"/>
                    <measurement group_id="B3" value="5.74" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (TG)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.42" spread="0.71"/>
                    <measurement group_id="B2" value="1.42" spread="0.68"/>
                    <measurement group_id="B3" value="1.42" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)</title>
        <description>Composite endpoint of MCE consists of cardiovascular death, AVR (aortic valve replacement) surgery, CHF(congestive heart failure) as a result of progression of aortic stenosis, nonfatal MI (myocardial infarction), CABG (coronary artery bypass) surgery, PCI (percutaneous coronary intervention), hospitalized unstable angina, and nonhemorrhagic stroke</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)</title>
          <description>Composite endpoint of MCE consists of cardiovascular death, AVR (aortic valve replacement) surgery, CHF(congestive heart failure) as a result of progression of aortic stenosis, nonfatal MI (myocardial infarction), CABG (coronary artery bypass) surgery, PCI (percutaneous coronary intervention), hospitalized unstable angina, and nonhemorrhagic stroke</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.591</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.960</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.826</ci_lower_limit>
            <ci_upper_limit>1.115</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events)</title>
        <description>Composite endpoint of AVE (aortic valve events) consists of AVR surgery, CHF (as a result of progression of AS), or cardiovascular death</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events)</title>
          <description>Composite endpoint of AVE (aortic valve events) consists of AVR surgery, CHF (as a result of progression of AS), or cardiovascular death</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                    <measurement group_id="O2" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.732</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.973</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.833</ci_lower_limit>
            <ci_upper_limit>1.137</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events)</title>
        <description>Composite endpoint of ICE (ischemic cardiovascular events) consists of cardiovascular death, nonfatal MI, CABG, PCI, hospitalized unstable angina, and nonhemorrhagic stroke</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events)</title>
          <description>Composite endpoint of ICE (ischemic cardiovascular events) consists of cardiovascular death, nonfatal MI, CABG, PCI, hospitalized unstable angina, and nonhemorrhagic stroke</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.780</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.628</ci_lower_limit>
            <ci_upper_limit>0.967</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiovascular Death</title>
        <description>Number of participants that experienced cardiovascular death</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Death</title>
          <description>Number of participants that experienced cardiovascular death</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.344</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.829</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.563</ci_lower_limit>
            <ci_upper_limit>1.222</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Aortic Valve Replacement (AVR)</title>
        <description>Number of participants that experienced aortic valve replacement (AVR)</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Aortic Valve Replacement (AVR)</title>
          <description>Number of participants that experienced aortic valve replacement (AVR)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                    <measurement group_id="O2" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.968</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.997</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.842</ci_lower_limit>
            <ci_upper_limit>1.179</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS)</title>
        <description>Number of participants that experienced Congestive Heart Failure (CHF) due to progression of aortic stenosis (AS)</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS)</title>
          <description>Number of participants that experienced Congestive Heart Failure (CHF) due to progression of aortic stenosis (AS)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.771</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.088</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.617</ci_lower_limit>
            <ci_upper_limit>1.917</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Nonfatal Myocardial Infarction (MI)</title>
        <description>Number of participants that experienced nonfatal myocardial infarction (MI)</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Nonfatal Myocardial Infarction (MI)</title>
          <description>Number of participants that experienced nonfatal myocardial infarction (MI)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.636</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.345</ci_lower_limit>
            <ci_upper_limit>1.173</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Coronary Artery Bypass Grafting (CABG)</title>
        <description>Number of participants that experienced coronary artery bypass grafting (CABG)</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Coronary Artery Bypass Grafting (CABG)</title>
          <description>Number of participants that experienced coronary artery bypass grafting (CABG)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.683</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.503</ci_lower_limit>
            <ci_upper_limit>0.929</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percutaneous Coronary Intervention (PCI)</title>
        <description>Number of participants that experienced percutaneous coronary intervention (PCI)</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percutaneous Coronary Intervention (PCI)</title>
          <description>Number of participants that experienced percutaneous coronary intervention (PCI)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.456</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.197</ci_lower_limit>
            <ci_upper_limit>1.057</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospitalization for Unstable Angina</title>
        <description>Number of participants that experienced hospitalization for unstable angina</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization for Unstable Angina</title>
          <description>Number of participants that experienced hospitalization for unstable angina</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.608</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.199</ci_lower_limit>
            <ci_upper_limit>1.860</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Nonhemorrhagic Stroke</title>
        <description>Number of participants that experienced nonhemorrhagic stroke</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Nonhemorrhagic Stroke</title>
          <description>Number of participants that experienced nonhemorrhagic stroke</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.647</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.124</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.682</ci_lower_limit>
            <ci_upper_limit>1.850</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Death (Any Cause)</title>
        <description>Number of participants that died (any cause)</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Death (Any Cause)</title>
          <description>Number of participants that died (any cause)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.799</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.788</ci_lower_limit>
            <ci_upper_limit>1.363</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Death Due to Cancer</title>
        <description>Number of participants that died due to cancer</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Death Due to Cancer</title>
          <description>Number of participants that died due to cancer</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.667</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.996</ci_lower_limit>
            <ci_upper_limit>2.791</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Incident Cancer</title>
        <description>Number of participants with incident cancer</description>
        <time_frame>Entire follow-up (median = 4.35 years)</time_frame>
        <population>One patient from the 944 patients randomized to ezetimibe/simvastatin 10/40 mg did not receive study medication and was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Incident Cancer</title>
          <description>Number of participants with incident cancer</description>
          <population>One patient from the 944 patients randomized to ezetimibe/simvastatin 10/40 mg did not receive study medication and was not included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="943"/>
                <count group_id="O2" value="929"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity (as continuous covariate)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.504</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.111</ci_lower_limit>
            <ci_upper_limit>2.035</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: Hazard Ratio of experiencing the endpoint on EZ/Simva 10/40 mg compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Transaortic Jet Velocity</title>
        <description>Mean change from baseline in peak transaortic jet velocity</description>
        <time_frame>Baseline to End of follow-up (median = 4.35 years) or pre-aortic valve replacement</time_frame>
        <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication. 180 patients were excluded from peak transaortic jet velocity due to missing measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Transaortic Jet Velocity</title>
          <description>Mean change from baseline in peak transaortic jet velocity</description>
          <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication. 180 patients were excluded from peak transaortic jet velocity due to missing measurements.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="859"/>
                <count group_id="O2" value="834"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.613" spread="0.586"/>
                    <measurement group_id="O2" value="0.618" spread="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.829</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline peak transaortic jet velocity</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.029</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.063</ci_lower_limit>
            <ci_upper_limit>0.051</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: EZ/Simva 10/40 mg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in Time Weighted Average Total Cholesterol From Baseline to End of Follow-up</title>
        <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
        <time_frame>Baseline to End of follow-up (median = 4.35 years)</time_frame>
        <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Time Weighted Average Total Cholesterol From Baseline to End of Follow-up</title>
          <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
          <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="916"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.8" spread="13.5"/>
                    <measurement group_id="O2" value="-2.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-32.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-33.3</ci_lower_limit>
            <ci_upper_limit>-31.0</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: EZ/Simva 10/40 mg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in Time Weighted Average Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to End of Follow-up</title>
        <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
        <time_frame>Baseline to End of follow-up (median = 4.35 years)</time_frame>
        <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Time Weighted Average Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to End of Follow-up</title>
          <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
          <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="916"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.8" spread="18.7"/>
                    <measurement group_id="O2" value="-3.8" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-50.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-51.8</ci_lower_limit>
            <ci_upper_limit>-48.2</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: EZ/Simva 10/40 mg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in Time Weighted Average High-density Lipoprotein Cholesterol (HDL-C) From Baseline to End of Follow-up</title>
        <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
        <time_frame>Baseline to End of follow-up (median = 4.35 years)</time_frame>
        <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Time Weighted Average High-density Lipoprotein Cholesterol (HDL-C) From Baseline to End of Follow-up</title>
          <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
          <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="916"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="17.7"/>
                    <measurement group_id="O2" value="2.5" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: EZ/Simva 10/40 mg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in Time Weighted Average Triglycerides From Baseline to End of Follow-up</title>
        <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
        <time_frame>Baseline to End of follow-up (median = 4.35 years)</time_frame>
        <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ/Simva 10/40 mg</title>
            <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Time Weighted Average Triglycerides From Baseline to End of Follow-up</title>
          <description>Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.</description>
          <population>Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="916"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.9" spread="27.6"/>
                    <measurement group_id="O2" value="5.1" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-20.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.6</ci_lower_limit>
            <ci_upper_limit>-17.3</ci_upper_limit>
            <estimate_desc>Direction of the Comparison: EZ/Simva 10/40 mg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EZ/Simva 10/40 mg</title>
          <description>Ezetimibe 10 mg + Simvastatin 40 mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="471"/>
                <counts group_id="E2" subjects_affected="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>AV dissociation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Heyde's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Necrotising oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>International normalised ratio</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Total lung capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Mechanical complication of implant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Corneal graft rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Secondary immunodeficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Intestinal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Neuroborreliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Peritonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Sternitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Asbestosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Drug administration error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Postoperative constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Postpericardiotomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Podagra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Articular calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>CREST syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Joint ankylosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Limb deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Myosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Spondylolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bone neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cerebellar tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Metastases to gallbladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Motor neurone disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Narcolepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Delusional disorder, persecutory type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Psychosomatic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nephritis interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Spermatocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Uterine malposition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cheyne-Stokes respiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Vasculitic rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Cardiac assistance device user</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Venous stasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="703"/>
                <counts group_id="E2" subjects_affected="706"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="929"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="943"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="929"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It is important to note that several of the ischemic outcomes making up the composite ischemic endpoint can occur as a causal consequence of aortic stenosis progression itself, or in association with its standard treatment (aortic valve replacement).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

